entertainment -WSS

entertainment

author：entertainment 2025-10-01 11:33:46 - browse：115

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： J&J expands global access to TB drug amid advocacy campaign

leisure time

entertainment

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Ahead of JPM, here's who's profiting most in health care

Europe sees delivery challenges ahead on Alzheimer's therapies

JPM: CVS says Medicare Advantage patients are impacting profits

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

focus

entertainment

hotspot

In age of alternative facts, a scholarly course on calling out crap

Who gets to use the title 'doctor'?

Novavax promises a turnaround & Lilly roils the obesity market

GSK Flovent asthma inhalers replaced by authorized generics

Alkermes shareholders re

Feng Zhang CRISPR delivery startup lays off quarter of staff

United colonoscopy coverage change 'may cost lives,' doctors say

Care demand spikes challenge UnitedHealth’s provider arm

FDA approval of Sarepta Duchenne genetic therapy gives me hope

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

knowledge

Does aspartame cause cancer? What new WHO guidance says

Chronically ill young patients struggle to find fertility info

J&J expands global access to TB drug amid advocacy campaign

Congress: Eradicate hepatitis C and reduce the deficit

Ahead of JPM, here's who's profiting most in health care

UCB departs biotech trade group BIO

leisure time

entertainment

Wikipedia

knowledge